Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Casdatifan With Itraconazole (Strong CYP3A4 Inhibitor) and Phenytoin (Strong CYP3A4 Inducer) in Healthy Adult Participants
Conditions
Interventions
Casdatifan
Itraconazole
+1 more
Locations
1
United States
Celerion
Tempe, Arizona, United States
Start Date
May 2, 2025
Primary Completion Date
October 18, 2025
Completion Date
October 18, 2025
Last Updated
November 13, 2025
NCT07310901
NCT06342713
NCT07401472
NCT07412353
NCT07280858
NCT07300189
Lead Sponsor
Arcus Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions